To investigate whether testosterone replacement therapy (TRT) reduces prostate cancer (PCa) risk via stabilizing serum testosterone (T) levels beyond simply elevating serum T levels and whether TRT reduces PCa risk due to low serum T levels at a young age.
We analyzed data of 776 hypogonadal men from a urology center in Bremerhaven, Germany through 2004-2016 to investigate whether the TRT group has more stable T levels and whether TRT can reduce the risk of PCa due to low serum T levels at an early age. We derived an index, Maximum Decline of T Relative to Baseline (MDRB), to describe the magnitude of T declines and variations over time.
We found the TRT group has more stable serum T levels (e.g. smaller drop-offs) during the follow-up period as compared to the non-TRT group, and the mean of MDRB is significantly higher in the untreated group (1.553 nmol/L VS 0.013 nmol/L; p-value < .001). TRT significantly reduces the risk of PCa associated with T deficiency at a young age (p-value = .00087).
TRT may reduce PCa risk via maintaining serum T levels within individual's normal range; T surveillance may be needed for males who have low serum T levels at a young age to monitor abnormal variations of T levels and ensure timely treatment when necessary to reduce PCa risk.
The aging male : the official journal of the International Society for the Study of the Aging Male. 2019 Mar 12 [Epub ahead of print]
Xiao Zhang, Yan Zhong, Farid Saad, Karim Sultan Haider, Ahmad Haider, Angela G Clendenin, Xiaohui Xu
a Department of Epidemiology and Biostatistics School of Public Health , Texas A&M University , College Station , TX , USA., b Department of Statistics , Texas A&M University , College Station , TX , USA., c Global Medical Affairs Andrology, Bayer AG, Berlin, Germany and Research Department , Gulf Medical University , Ajman , UAE., d Private Urology Practice , Bremerhaven , Germany.